Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 1
2013 3
2014 7
2015 6
2016 14
2017 12
2018 11
2019 21
2020 17
2021 37
2022 35
2023 25
2024 36
2025 30
2026 26

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

254 results

Results by year

Filters applied: . Clear all
Page 1
Primary Angiitis of the CNS: A Systematic Review and Meta-analysis.
Beuker C, Strunk D, Rawal R, Schmidt-Pogoda A, Werring N, Milles L, Ruck T, Wiendl H, Meuth S, Minnerup H, Minnerup J. Beuker C, et al. Among authors: ruck t. Neurol Neuroimmunol Neuroinflamm. 2021 Oct 18;8(6):e1093. doi: 10.1212/NXI.0000000000001093. Print 2021 Nov. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34663675 Free PMC article.
Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases.
Düsing C, Györfi AH, Stütz AN, Lahu LM, Deicher FS, Li YN, Bruch PM, Matei AE, Micu A, Filla T, Koziel S, Hölscher AS, Röhrich M, Lorenz HM, Cramer M, Antoch G, Timm J, Abusabha Y, Ruck T, Homey B, Kreuter A, Buehring B, Radujkovic A, Heußel CP, Hagen M, Grieshaber-Bouyer R, Schett G, Brunn A, Dietrich S, Merkt W, Distler JHW. Düsing C, et al. Among authors: ruck t. Nat Med. 2026 Apr;32(4):1530-1542. doi: 10.1038/s41591-026-04238-4. Epub 2026 Feb 19. Nat Med. 2026. PMID: 41714747 Free PMC article.
TREK-king the blood-brain-barrier.
Bittner S, Ruck T, Fernández-Orth J, Meuth SG. Bittner S, et al. Among authors: ruck t. J Neuroimmune Pharmacol. 2014 Jun;9(3):293-301. doi: 10.1007/s11481-014-9530-8. Epub 2014 Feb 21. J Neuroimmune Pharmacol. 2014. PMID: 24557892 Review.
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
Schoser B, Roberts M, Byrne BJ, Sitaraman S, Jiang H, Laforêt P, Toscano A, Castelli J, Díaz-Manera J, Goldman M, van der Ploeg AT, Bratkovic D, Kuchipudi S, Mozaffar T, Kishnani PS; PROPEL Study Group. Schoser B, et al. Lancet Neurol. 2021 Dec;20(12):1027-1037. doi: 10.1016/S1474-4422(21)00331-8. Lancet Neurol. 2021. PMID: 34800400 Clinical Trial.
Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients.
Nelke C, Stascheit F, Eckert C, Pawlitzki M, Schroeter CB, Huntemann N, Mergenthaler P, Arat E, Öztürk M, Foell D, Schreiber S, Vielhaber S, Gassa A, Stetefeld H, Schroeter M, Berger B, Totzeck A, Hagenacker T, Meuth SG, Meisel A, Wiendl H, Ruck T. Nelke C, et al. Among authors: ruck t. J Neuroinflammation. 2022 Apr 12;19(1):89. doi: 10.1186/s12974-022-02448-4. J Neuroinflammation. 2022. PMID: 35413850 Free PMC article.
C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis.
Huntemann N, Gerischer L, Herdick M, Nelke C, Stascheit F, Hoffmann S, Öztürk M, Schroeter CB, Lehnerer S, Stein M, Schubert C, Schneider-Gold C, Pfeuffer S, Krämer HH, Konen FF, Skripuletz T, Pawlitzki M, Glaubitz S, Zschüntzsch J, Scherwietes V, Totzeck A, Hagenacker T, Meuth SG, Meisel A, Ruck T. Huntemann N, et al. Among authors: ruck t. J Neurol Neurosurg Psychiatry. 2025 Mar 24;96(4):310-321. doi: 10.1136/jnnp-2024-334404. J Neurol Neurosurg Psychiatry. 2025. PMID: 39798960 Free PMC article.
Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab.
Meuth SG, Wolff S, Mück A, Willison A, Kleinschnitz K, Räuber S, Pawlitzki M, Konen FF, Skripuletz T, Grothe M, Ruck T, Huttner HB, Kleinschnitz C, Bopp T, Pul R, Cree BAC, Hartung HP, Möllenhoff K, Pfeuffer S. Meuth SG, et al. Among authors: ruck t. Ann Neurol. 2025 Mar;97(3):583-595. doi: 10.1002/ana.27143. Epub 2024 Nov 25. Ann Neurol. 2025. PMID: 39582359 Free PMC article.
254 results